Mass General Brigham Ventures

Activity from announced rounds

All recorded activity
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$130.8M
3 disclosed · full round size, not this investor’s share

By stage

Seed1
Series A1
Series C+1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in all activity
Oyster Therapeutics

Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.

$60MSeries A-2
Participant
Abcuro

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

$66MSeries D
Role not disclosed
Violet Therapeutics

Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform

$4.8MSeed+
Role not disclosed